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Running head:  Preload of MSC infusion rescues erectile function in cavernous nerve 
injury 
 
Take Home Message:  
 
Intravenous delivery of mesenchymal stem cells (MSCs) prior to a cavernous nerve 
(CN) injury model for experimental erectile dysfunction (ED), resulted in increased 
intracavernous pressure (ICP) / arterial pressure (AP), neuronal innervation and 
higher levels of GDNF and Neurturin mRNA in the major pelvic ganglia (MPG). 
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Abstract 
Introduction: 
 We evaluated the potential preventive effects and mechanisms of intravenously 
preloaded mesenchymal stem cells (MSCs) for erectile dysfunction (ED) in a 
cavernous nerve (CN) injury model.  
Methods:  
Male Sprague Dawley rats were used for this study. Rats were randomized into two 
groups. One group was intravenously preloaded with MSCs (1.0×10
6
 cells in 1 ml 
total fluid volume) and the other was infused with medium alone (1ml DMEM) for 
sham control, respectively. Crushed CN injury was induced immediately after 
infusion. The surgeon was blind to the experimental conditions (MSC or medium). 
Main Outcome Measures: 
To assess erectile function, we measured the intracavernous pressure (ICP) and 
arterial pressure (AP) at 1 hour and 2 weeks after CN injury.  After measuring the 
initial ICP/AP of pre-injury (normal) male SD rats, they were randomized into the two 
groups and infused with MSCs or medium.  PKH26-labelled MSCs were used for 
tracking. To investigate the mRNA expression levels of neurotrophins in the major 
pelvic ganglia (MPG), we performed real-time quantitative RT-PCR. 
Results: 
 The reduction of ICP/AP and area under the curve of ICP (ICP-AUC) in the MSC 
group was significantly lower than in the DMEM group (P<0.05; P<0.05) at one hour. 
The ICP/AP and ICP-AUC at 2 weeks post-injury in the MSC group was significantly 
higher than in the DMEM group (P<0.01; p<0.05). The preloaded PKH26-labelled 
MSCs were detected in the MPG and CN using confocal microscopy indicating 
homing of the cells to the injured nerve and ganglia. GDNF and neurturin, which are 
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important neurotrophic factors for erection, had expression levels in MPG 
significantly higher in the MSC group than in the DMEM group (P<0.01, 0.05). 
Conclusion: Intravenous preload of MSCs before a CN injury may prevent or reduce 
experimental ED. 
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1. Introduction 
Radical prostatectomy (RP) is a recommended curative procedure for patients 
with low and intermediate risk in localized prostate cancer and is associated with a 
life expectancy of more than 10 years 
1
. Erectile dysfunction (ED) following RP, 
however, is the major problem and it can reduce patients’ quality of life (QOL) after 
surgery 
2, 3
. The etiology of ED after RP is considered to be multifactorial 
4-6
, but a 
neurogenic etiology resulting from cavernous nerve (CN) injuries during a nerve-
sparing procedure is important
7
.  
  Despite the progress of nerve sparing techniques that include spreading the 
robot-assisted procedures, recent post-operative ED rates at one year ranged from 10 
to 46% 
8
. Common drug therapy is oral intake of phosphodiesterase type 5 inhibitors, 
but the success rate is significantly lower in this population 
9
. Penile rehabilitation is 
also beneficial treatment for these populations, but the effectiveness is limited and it 
takes several months to years to recover 
4
. Therefore, it is an important research issue 
to develop approaches to better reduce post-operative ED in patients. 
Mesenchymal stem cells (MSCs) derived from adult bone marrow are considered 
to secrete a number of neurotrophic factors, cytokines and anti-inflammatory 
molecules that provide neuroprotection, induction of axonal regeneration/sprouting, 
remyelination and immunomodulation 
10
. Much work in animal models and clinical 
trials have shown that intravenous infusion of MSCs following peripheral nerve injury 
including sciatic  
11
 and recurrent laryngeal 
12
 nerve injuries and central nervous 
diseases such as stroke 
13-15
 and spinal cord injury 
16
 is safe and improves functional 
recovery. In this study we evaluated the effects of systemically delivered MSCs in an 
experimental ED model in the rat.  
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2. Aim 
The aim of this study is to find a cell therapy approach to prevent or reduce post-
operative ED using intravenous delivery of MSCs prior to induction of CN injury in 
the rat. 
 
3. Materials and Methods 
3.1. Preparation of mesenchymal stem cells from rat bone marrow 
The use of animals in this study was approved by the animal care and use 
committee at Sapporo Medical University (#12-030), and all procedures were carried 
out in accordance with institutional guidelines. Methodology of MSC culture was 
based upon our previous studies 
17
. Briefly, bone marrow was obtained from femoral 
bones in adult Sprague–Dawley rats (male, 200-250 g), diluted to 25 ml with 
Dulbecco's modified Eagle's medium (DMEM) (SIGMA, St. Louis, MO, USA) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Thermo Fisher 
Scientific Inc., Waltham, MA, USA), 2 mM l-glutamine (SIGMA), 100 U/ml 
penicillin, 0.1 mg/ml streptomycin (Thermo Fisher Scientific Inc.) and incubated for 3 
days (5% CO2, 37 °C).  When cultures almost reached confluence, the adherent cells 
were detached with trypsin-EDTA solution (SIGMA) and subcultured at 1 × 10
4
 
cells/ml. In the present study, we have used MSCs after three passages. 
 
3.2. Cavernous nerve injury model and assessment of erectile function 
Male Sprague-Dawley rats weighing 250–350 g were anesthetized with 
pentobarbital (45 mg/kg). Through a lower abdominal midline incision, bilateral 
major pelvic ganglia (MPG) and CNs were identified and exposed. The CNs 
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(approximately 5 mm distal to the MPG) were first crushed using a micro needle 
holder (FD231R, B. Braun Aesculap Japan, Tokyo, Japan) for 15 sec as previously 
described with minor modification
18
.  The procedure was carried out carefully so as 
not to cut the CNs to avoid major injury causing deterioration of erectile function. 
Abdominal wounds were then closed with sutures, and animals were allowed to 
recover from anesthesia.  
The intracavernous pressure (ICP) and arterial pressure (AP) were measured using 
the methods similar to those previously reported 
19-22
.  Animals were anesthetized 
with pentobarbital (45 mg/kg). The skin of the left neck was incised and a PE50 
(#427400, Becton Dickinson, MD, USA) tube was inserted into the left carotid artery 
to monitor AP. Bilateral MPG and CNs were exposed as described above and the 
incision was extended to the skin around the penis. A 23G needle connected to a PE50 
tube filled with heparinized saline (250 IU/ml) was inserted into the left penile crus. 
Electrostimulation (20 Hz and 1.5mA for 60 seconds) of the CNs was applied with a 
bipolar hook electrode (TF-206-011, Unique Medical Co., Tokyo, Japan), and 
changes of ICP were measured. Maximal ICP, mean AP and area under the curve of 
ICP (ICP-AUC) during the period of electrostimulation were analyzed using LabChart 
(ADinstruments Inc., Colorado Springs, CO, USA). The maximal ICP value divided 
by simultaneous mean AP (ICP/AP) and ICP-AUC were used to evaluate erectile 
function.   
 
3.3. Experimental protocol (Fig.1)  
First, we measured the initial ICP/AP from pre-injury rats. The rats were 
randomized into experimental and sham control groups (MSC and DMEM). Rats 
were intravenously infused with MSCs (1.0×10
6
 cells in 1ml total fluid volume) and 
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medium alone (fresh 1 ml DMEM only) respectively via right external jugular vein.  
CN injury was immediately induced after preload of MSCs or DMEM. The order of 
delivering MSC or DMEM was randomized. The surgeon (A.T.) did not know 
whether MSC or DMEM was administered before and during infusion. We measured 
ICP/AP at 1 hour and 2 weeks after CN injury. Each ICP/AP measurement at 1 hour 
(n=12/group) and 2 weeks (n=10/group) was a terminal experiment in a separate 
group. 
 
3.4. Retrograde tracing study 
Fluorogold (FG: Hydroxystilbamidine, methanesulfonate, H-22845, Thermo 
Fisher Scientific Inc.) injection was performed one week before histological 
examination as previously reported 
19, 22, 23
. Briefly, animals were anesthetized with 
pentobarbital (45 mg/kg). The skin beside the penis was narrowly opened and 4µl of 
FG (4.0%) was injected into the right penile crus by using a 30G Hamilton syringe. 
After the ICP measurement the right MPG was collected and immediately fixed in 4% 
paraformaldehyde (PFA) for about 48 hours, and then immersed in 0.1 mol/L 
phosphate buffer (PB) containing 25% sucrose.   
Quantification of retrograde labeled FG positive cells was performed as 
previously described. 
20, 24, 25
 Serial frozen transverse sections (14 µm thick) of the 
entire MPG were cut with a cryostat.  Every sixth section was mounted on 3 
aminopropyltriethoxysilane-coated slides (12–14 sections per animal). Images of each 
MPG were taken under fluorescent microscope through a wideband UV filter using 
40x objective. We evaluated all FG positive neuronal profiles that had nuclei in each 
MPG section to avoid double-counting of neurons (10 rats each in the MSC and the 
DMEM groups). The standardized selection of sections through the entire MPG and 
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counting all FG positive cells on each section allowed an unbiased assessment of 
retrogradely labelled cells between the MSC and DMEM groups spanning the entire 
MPG.   
 
3.5. Detection of PKH26 labeled MSCs 
Cells were prelabeled with the membrane dye PKH26 as previously reported 
10
. 
Intracardiac perfusion (4 % PFA) (n=10) were performed immediately after CN injury 
to collect MPGs and CNs and store at -80 ℃ until use. Transverse cryostat sections 
(20 µm) were obtained through the lesion area. Immunohistochemistry was performed 
using anti-neurofilament (#N4142, Sigma; 1:500).  The sections were examined using 
a confocal microscopy with Ex/Em (405; 488; 561: LSM780 ELYRA system; Carl 
Zeiss, Oberkochen, Germany). 
 
3.6. Real-Time Polymerase Chain Reaction 
One hour after nerve injury, animals (n=5/group) were anesthetized, and the 
MPGs were collected in each group using a microscope. Total RNA was extracted 
using a RNeasy Plus Mini kit (#74134, Qiagen, Valencia, CA, USA) according to the 
manufacturer’s instructions 
21, 25
. The concentration of the RNA was quantified by 
determination of optical density at 260 nm. The RNA (1µg) was reverse transcribed 
into cDNA using SuperScript III reverse transcriptase (Qiagen) and nucleotide oligo-
dT. Real-time polymerase chain reaction (PCR) for each sample was performed in 
triplicates with TaqMan Universal Master Mix II with UNG (Thermo Fisher 
Scientific Inc.). Specific sets of primers and TaqMan probes were purchased from 
Thermo Fisher Scientific Inc.: glyceraldehyde-3-phospate dehydrogenase (GAPDH) 
(TaqMan rodent GAPDH control reagents, Rn01775763-g1) as an endogenous control, 
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GDNF (Rn00569510_m1) and Neurturin (Rn01527513-g1) as target genes. The 
reactions were run in an ABI-StepOne real-time PCR system (Thermo Fisher 
Scientific Inc.) using the 48-well plate format. The cycling conditions included an 
initial phase at 95°C for 3 min, followed by 40 cycles at 95°C for 15 s, and 55°C for 
60 s. Relative quantification of target gene expression was calculated using the 
comparative threshold cycle method according to the guidelines of the manufacturer. 
 
3.7. Statistical analysis 
All statistical analyses were performed using SPSS 18 (SPSS, Inc., IL, USA).  For 
multiple comparisons, we used Kruskal-Wallis one-way analysis of variance followed 
by Bonferroni post hoc test. Comparison between two groups was performed using 
the Mann-Whitney U-test.  
 
4. Results 
4.1. Erectile function after MSC transplantation  
To assess the erectile function, a physiological study with ICP/AP and ICP-AUC 
analyses was carried out. Representative waveforms of the ICP and AP at pre-injury 
in the MSC group (Fig. 2A), pre-injury in the DMEM group (Fig. 2B), 1 hour after 
injury in the MSC group (Fig. 2C) and 1 hour after injury in the DMEM group (Fig. 
2D) are shown in Fig. 2. The ICP/AP and ICP-AUC were significantly decreased one 
hour after injury in both groups (Fig. 2E, 2F: P<0.01). The reduction of ICP/AP in the 
MSC group (54.7%) was 12.4% lower than in the DMEM group (67.1%) at 1 hour 
after transplantation. (Fig. 2E, P<0.05). The reduction of ICP-AUC in the MSC group 
(60.2%) was 12.3% lower than in the DMEM group (72.5%) at 1 hour after 
transplantation (Fig. 2F, P<0.05).  
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Representative waveforms of the ICP and AP at 2 weeks after transplantation in 
the MSC group (Fig. 3A) and the DMEM group (Fig. 3B) are shown in Fig. 3. It 
should be noted that waveform of the MSC group (Fig. 3A) shows similar trends as 
the one of pre-injury state (Fig. 2A). No change of the waveform in the DMEM 
groups at both 1 hour (Fig. 2D) and 2 weeks (Fig. 3B) was observed.  The ICP/AP in 
the MSC group (0.65±0.04) was 41.3% higher than in the DMEM group (0.46±0.04) 
at 2 weeks after transplantation (Fig. 3C, P<0.01). The ICP-AUC in the MSC group 
(5695±553 cmH2O) was 53.7% higher than in the DMEM group (3705±527cmH2O) 
at 2 weeks after transplantation. (Fig. 3D, P<0.05). The MSC-preloaded group 
displayed less ED shortly after CN injury (Fig.2) and erectile function evaluated with 
physiological analyses reached near normal values over the time course of two weeks 
(Fig.3). Collectively, these results indicate that the intravenous preload of MSCs 
prevented or reduced ED after RP. 
 
4.2. FG-positive cells in the MPGs 
To assess the degree of neuronal survival, a retrograde tracing study using FG was 
carried out. Representative sections from four DMEM (Fig. 4A-D) and four MSC 
(Fig.4 E-H) animals are shown in Fig. 4A-H.  However, we counted the number of 
FG-positive cells in the entire MPG in both groups. The mean number of FG-positive 
cells was 58.3±4.7 (cells/MPG) in the MSC group as compared to the DMEM group 
(36.9±3.8 cells/animal) (P<0.01) at 2 weeks after CN injury (Fig.4I). This indicated 
that there was 58.0 % higher number of FG detected neurons in the MSC treated rats.  
 
4.3. Distribution of transplanted PKH26-labelled MSCs (PKH26-MSCs) in the 
injured lesion site 
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The PKH26-MSCs (red) survived and distributed to the lesion sites. The 
distribution of the transplanted PKH26-MSCs demonstrates a homing effect into the 
MPGs (5-10 cells/slide) and lesioned CNs (10-20 cells/slide) in relation to the 
neurofilament stained axons after systemic delivery (Fig. 5A, B). To determine if 
autofluorescence of the MSCs was present at the wavelengths used to study PKH26 
fluorescence, we examined MPGs and CNs of animals infused MSCs without labeling 
PKH26. No red cells were observed in these lesions (Fig 5C, D).  
 
4.4. Expression of GDNF and Neurturin mRNA after transplantation 
To investigate the expression levels of GDNF and Neurturin mRNA in the MPGs, 
we performed real-time quantitative RT-PCR. GDNF and Neurturin are neurotrophic 
factors in MPG that are important for erection 
26, 27
. Relative expression levels of 
GDNF mRNA (Fig 6A) in MPG was significantly higher (3.6 fold) in the MSC group 
(7.22±2.59) compared to the DMEM group (2.02±1.27) (P<0.01) and the relative 
expression level of Neurturin mRNA (Fig 6B) in MPGs was also significantly higher 
(2.4 fold) in the MSC group (4.03±1.84) compared to the DMEM group (1.67±0.65) 
(P<0.05).  
 
5. Discussion 
The primary objective of this study was to develop a new approach to prevent or 
reduce post-operative ED with intravenous preload of MSCs in a CN injury rat model. 
Intravenous preload of the MSC-infused group exhibited a significant preservation of 
erectile function. Erectile functional in the MSC transplanted animals as assessed 
using ICP/AP and ICP-AUC analysis was significantly preserved compared to the 
control group. A retrograde tracing study using FG also demonstrated that the number 
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of FG-positive cells in the MPG was higher in the MSC group compared to the 
control group. MSCs labeled with PKH26 that is known to have a long half-life in 
vivo, were found in the both MPGs and injured CNs after the transplantation. We 
observed significantly higher expression of GDNF and neurturin mRNA in MPG in 
the MSC group by real-time quantitative RT-PCR. These results suggest that 
intravenous preload (delivered before the surgical procedure) of MSCs rescues 
erectile function by neuroprotection in a rat model of cavernous nerve injury. Given 
that prostatectomy surgery unlike traumatic disorders is timed, the preparation and 
pre-delivery of MSCs before surgery is practical.  Thus, the therapeutic effects of 
MSCs could have a more immediate beneficial effect. 
Although the post-operative ED occurred in both groups, the MSC-preloaded 
group displayed less ED shortly after CN injury (Fig. 2) and significant improvement 
at 2 weeks (Fig. 3) evaluated with physiological analyses suggesting that the ED in 
the MSC group gradually improved over time. Acute accumulation (less than 1 hour) 
of the intravenously preloaded PKH-labelled MSCs observed in the MPG neurons and 
injured CNs might provide neuroprotection. Fandel et al. reported that 
intracavernously injectioned adipose-derived stem cells were detected in the MPG and 
found the elevation of stromal cell-derived factor-1 (SDF-1) in the MPG 
18
. SDF-1 is 
a chemokine that has been implicated in cell recruitment (homing) after stem cell 
infusion 
18
. MSCs also have a tendency to home to damaged lesion sites and enhance 
their therapeutic effectiveness with similar molecular mechanisms 
28
.   
Elevation of GDNF and neurturin mRNA in MPG was associated with the 
preservation of the erectile function in the MSC group. GDNF and neurturin are two 
of the neurotrophic factors acting in the MPG for erection
26
.  Kato et al. demonstrated 
that the recovery from ED after CN crush was facilitated when GDNF and neurturin 
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were administered into nerves with herpes simplex virus vector-mediated delivery
20, 
23
.  Another possible therapeutic mechanisms of intravenously transplanted MSCs in 
various models of nervous diseases are not only differentiation to neuronal and/or 
glial cells, but also secretion of neurotrophic factors which can provide for 
neuroprotection, regeneration, recruitment of progenitors, facilitation of endogenous  
neurotrophic secretion, induction of axonal sprouting, remyelination and modulation 
of inflammatory/immune responses 
10, 29
. Recent studies also suggested the 
involvement of paracrine pathways. Paracrine action might be an important 
mechanism for erectile function by which transplantation of MSCs facilitate 
regeneration in corpus cavernosum after CN injury 
30, 31
.  
Preloaded MSCs could circulate in the blood stream and home to the injured 
tissues such as MPGs and injured CNs when the insults occurred and the distributed 
these cells could have therapeutic efficacy for post-operative ED.  In experimental 
erectile function, several studies using intracavernous injection of MSCs have been 
reported therapeutic effects
32
. Yet, there are few studies using intravenous infusion of 
MSCs for ED. Intravenous preloading of MSCs, which may home to MPG and 
injured CNs after the CN injury, would be less invasive than intracavernous injection. 
The other potential merit of intravenous infusion of the MSCs is that infused MSCs 
accumulated not only in the injured CNs but also in the MPG providing significant 
recovery of erectile function after CN injury. Given that intravenous infusion of 
MSCs derived from bone marrow has been used in a number of clinical studies with 
demonstrated safety the prospect of using MSCs as an adjunct therapy for damaged 
nerve repairs should be considered. Functional improvement after intravenously 
delivered MSCs has been reported in several clinical studies dealing with other 
neurological diseases 
13, 15
. Currently, clinical trials with direct injection of adipose-
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derived MSCs for ED (ClinicalTrials.gov Identifier: NCT02087397; NCT02240823) 
are listed and the intravenous infusion of bone marrow-derived MSCs for other 
neurological diseases such as cerebral stroke, spinal cord injury are also ongoing 
13, 15
.  
Whether intravenous infusion of MSCs for prostate cancer promotes progression 
or not is still controversy. There are several papers evaluating in progression of 
experimental prostate cancer, most of them concluded MSC had no adverse effects on 
progression of prostate cancer
33, 34
. We can also select the patients with low-risk by 
combined information of MRI, biopsy Gleason score, and preoperative PSA level 
before RP. Although we agree that the intravenous infusion of MSCs would be 
contraindicated in case of aggressive cancers 
35
 , twelve-year cancer specific survival 
was reported more than 95% for patients with low risk prostate cancer who received 
RP 
36
. Therefore, intravenous infusion of MSCs before RP for these selected patients 
might be safe in terms of recurrence, progression and overall survival. 
Our study has limitations. In this study, we focused on the primary change by 
assessment of the degree of neural survival to examine FG-positive cells in the MPG 
and found that the number of FG-positive cells in the MPG was higher in the MSC 
group compared to the control group indicating greater neuronal connectivity. We 
also performed the ICP/AP and ICP-AUC analysis to examine erectile function and 
found that post-operative ED was prohibited in the MSC group. Since we did not 
focus on the secondary change, we did not assess the expression of nNOS and eNOS 
in the cavernous nerves and in the penis, which play a major role in erection and are 
impaired after CN injury. Future studies will be performed to elucidate the molecular 
mechanism remains to be determined.  
In summary our results indicate that intravenous preload of MSCs prevents or 
reduces post-operative ED in a CN injury model. Potential mechanisms include 
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distribution of the  transplanted cells to the lesion area where they may provide 
neuroprotection and prevent neuropraxia. It should be noted that we infused MSCs 
before CN injury, suggesting that preload of MSCs can rescue erectile function.. 
Finally it may be possible to combine MSC therapy with other current penile 
rehabilitation therapies to achieve maximal function. 
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Figure legends 
 
Figure 1 
A timeline for experiments is shown. Animals were first assessed by ICP/AP. 
They were randomized to two groups and preloaded (MSC and DMEM groups), then 
induced CN injury. The ICP/AP was measured at 1 hour and two weeks. Tissue 
sampling for histological analyses were performed at 1 hour and 2 weeks.  
 
Figure 2 
ICP response to electrostimulation of CNs at 1 hour. ICP along with AP 
(ICP/AP): (A) in the pre-injury, MSC group, (B) pre-injury, DMEM group, (C) post 1 
hour, MSC group, (D) post 1 hour, DMEM group. Quantitative analyses of erectile 
function as evidence by ICP/AP (E) and ICP-AUC (F). ICP/AP and ICP-AUC at 1 
hour after injury in the MSC group was significantly higher compared to the ICP/AP 
at 1 hour after injury in the DMEM group (* P<0.05). The ICP/AP and ICP-AUC 
were significantly decreased one hour after injury in the both groups (** P<0.01). 
Black bars under the x axis indicate 1min period of stimulation.  
 
Figure 3 
ICP response to electrostimulation of CNs at 2 weeks.  ICP along with AP 
(ICP/AP): (A) MSC and (B) DMEM groups. Rats preloaded MSCs exhibited 
significant recovery of ICP/AP and ICP-AUC compared to the DMEM group. 
Quantitative analyses of erectile function as evidence by ICP/AP (C) and ICP-AUC 
(D). The ICP/AP and ICP-AUC at 2 weeks after injury in the MSC group was 
significantly higher compared to the DMEM group (** P<0.01, * P<0.05). Black bars 
under the x axis indicate 1min period of stimulation. 
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Figure 4 
Representative images of FG-positive cells in the MPGs from four animals per 
group 2 weeks after transplantation; (A-D) DMEM, (E-H) MSC groups. (I) The MSC 
group had more FG-positive cells in MPGs than DMEM group. ** p<0.01. Scale 
bar=250µm. 
 
Figure 5 
Transverse sections and immunohistochemical analysis of injured MPG (A) 
and CN (B) and intravenous preload of PKH26-MSCs. Demonstration of distributed 
infused PKH26-MSCs (red: white arrows) and stained with neurofilament (green). 
Endogenous cells stained with DAPI (blue). Note that we infused MSCs without 
labeling PKH26 and no red cells were observed in the MPGs (C) and CNs (D). Scale 
bar=150µm. 
 
Figure 6 
mRNA expression of GDNF (A) and Neurturin (B) in MPGs after intravenous 
preload of MSCs at 1 hour. Relative expression level of GDNF and Neurturin mRNA 
in MPGs was significantly higher in the MSC group (P<0.01, 0.05).  
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